Time-series clustering of cytokine expression after transarterial chemoembolization in patients with hepatocellular carcinoma

Cytokines play an important role in the development of tumors. The purpose of the present study was to evaluate the mechanisms and cytokine level changes after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). The Short Time-series Expression Miner (STEM) program was utilized to cluster cytokine expression profiles from the day before TACE to day 21 post-TACE. Based on the identified significant signatures, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway analyses were performed. Cytokines were serially monitored in 60 evaluable patients to identify the results of the STEM program. Examination of the significant signatures identified 6 significant time-varied expression patterns for 507 cytokines (profiles 16, 18, 28, 41, 42 and 43). GO analysis was enriched in ‘cytokine receptor-binding’ and ‘cytokine receptor activity’, and the identified signaling pathways included ‘cytokine-cytokine receptor interaction’ and the ‘JAK-STAT signaling pathway’. Ciliary neurotrophic factor (CNTF) level was increased early after TACE, reaching a peak on day 7 before finally decreasing from day 14 onwards, and was significantly positively correlated with aminotransferase level. Serum levels of pre-TACE IL-10 predicted the local tumor response and overall survival (OS) of the patients, while serum levels of post-TACE IL-1β only indicated the local tumor response of the patient. Overall, the present study identified cytokine time-series expression profiles of patients with HCC undergoing TACE. Early phase increases in CNTF after TACE were associated with post-treatment hepatic injury. IL-1β may reflect an objective response after TACE, while IL-10 may represent a biomarker for OS and the objective response pre-TACE, which may help patients with HCC to benefit from TACE.

[1]  S. Opal,et al.  Anti-inflammatory cytokines. , 2000, Chest.

[2]  T. Patel Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States , 2001, Hepatology.

[3]  Christian von Mering,et al.  STRING: a database of predicted functional associations between proteins , 2003, Nucleic Acids Res..

[4]  G. Salles,et al.  Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. , 2004, Blood.

[5]  M. Chou,et al.  The involvement of genetic polymorphism of IL-10 promoter in non-small cell lung cancer. , 2005, Lung cancer.

[6]  Ziv Bar-Joseph,et al.  STEM: a tool for the analysis of short time series gene expression data , 2006, BMC Bioinformatics.

[7]  E. Nkenke,et al.  The interleukin-10 (-1082A/G) polymorphism is strongly associated with increased risk for oral squamous cell carcinoma. , 2008, Anticancer research.

[8]  Jianren Gu,et al.  Ciliary neurotrophic factor receptor α subunit–modulated multiple downstream signaling pathways in hepatic cancer cell lines and their biological implications , 2007, Hepatology.

[9]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[10]  H. Yoshikawa,et al.  Interleukin-10 -1082 gene polymorphism and susceptibility to cervical cancer among Japanese women. , 2010, Japanese journal of clinical oncology.

[11]  T. Mcclanahan,et al.  IL-10 elicits IFNγ-dependent tumor immune surveillance. , 2011, Cancer cell.

[12]  Francis J. Huber,et al.  Th17 cells express interleukin-10 receptor and are controlled by Foxp3⁻ and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. , 2011, Immunity.

[13]  X. Bai,et al.  Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. , 2012, Cancer research.

[14]  Yozo Sato,et al.  Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602 , 2013, Upsala journal of medical sciences.

[15]  Seungok Lee,et al.  Change in inflammatory cytokine profiles after transarterial chemotherapy in patients with hepatocellular carcinoma. , 2013, Cytokine.

[16]  Qi Zhang,et al.  Wnt/β-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1α signaling. , 2013, Carcinogenesis.

[17]  P. Zou,et al.  Genetic association of interleukin-10 promoter polymorphisms and susceptibility to diffuse large B-cell lymphoma: a meta-analysis. , 2013, Gene.

[18]  F. Gounari,et al.  Current status of interleukin-10 and regulatory T-cells in cancer , 2013, Current opinion in oncology.

[19]  T. Utsunomiya,et al.  High STAT4 Expression is a Better Prognostic Indicator in Patients with Hepatocellular Carcinoma After Hepatectomy , 2014, Annals of Surgical Oncology.

[20]  Á. Mena,et al.  Factors associated with recurrence and survival in liver transplant patients with HCC--a single center retrospective study. , 2015, Annals of hepatology.

[21]  Wesam A. Nasif,et al.  Serum Cytokine of IL-10 and IL-12 in Chronic Liver Disease: The Immune and Inflammatory Response , 2015, Disease markers.

[22]  Jin Hyoung Kim,et al.  Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. , 2015, World journal of gastroenterology.

[23]  J. Gray,et al.  IL-10 and integrin signaling pathways are associated with head and neck cancer progression , 2016, BMC Genomics.

[24]  L. Kenner,et al.  JAK-STAT signaling in cancer: From cytokines to non-coding genome. , 2016, Cytokine.

[25]  Luc Girard,et al.  ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. , 2016, Cell reports.

[26]  Weiqi Wang,et al.  Interleukin-10 deficiency impairs regulatory T cell-derived neuropilin-1 functions and promotes Th1 and Th17 immunity , 2016, Scientific Reports.

[27]  R. Li,et al.  Semi-quantitative assessment of the presence and Child-Pugh class of hepatitis B related cirrhosis by using liver lobe-based dynamic contrast-enhanced MRI. , 2016, Clinical radiology.

[28]  C. Trautwein,et al.  Functional role of CCL5/RANTES for HCC progression during chronic liver disease. , 2017, Journal of hepatology.

[29]  T. Gamblin,et al.  Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. , 2017, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[30]  M. Honda,et al.  Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study , 2017, BMC Cancer.

[31]  Moudi Al-Nashmi,et al.  Interleukin 1 receptor antagonist and 2'-5'-oligoadenylate synthetase-like molecules as novel biomarkers for multiple sclerosis patients in Bahrain. , 2017, Multiple sclerosis and related disorders.

[32]  Ke Chen,et al.  Human MSCs promotes colorectal cancer epithelial–mesenchymal transition and progression via CCL5/β-catenin/Slug pathway , 2017, Cell Death and Disease.

[33]  Priya Bhardwaj,et al.  Obesity alters the lung myeloid cell landscape to enhance breast cancer metastasis through IL5 and GM-CSF , 2017, Nature Cell Biology.

[34]  Mingxia Cui,et al.  Ciliary neurotrophic factor analogue aggravates CCl4-induced acute hepatic injury in rats. , 2017, Canadian journal of physiology and pharmacology.

[35]  I. Ellis,et al.  IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients , 2017, Cancer Immunology, Immunotherapy.

[36]  C. Sirlin,et al.  Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis , 2017, Abdominal Radiology.

[37]  T. Pawlik,et al.  Personalized treatment of patients with very early hepatocellular carcinoma. , 2017, Journal of hepatology.

[38]  Fernando Alarid-Escudero,et al.  An Overview of R in Health Decision Sciences , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[39]  Minoru Kanehisa,et al.  KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..

[40]  R. Sacco,et al.  Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review , 2017, Journal of hepatocellular carcinoma.

[41]  Qi Zhang,et al.  Hypoxia‐inducible factor‐1α/interleukin‐1β signaling enhances hepatoma epithelial–mesenchymal transition through macrophages in a hypoxic‐inflammatory microenvironment , 2018, Hepatology.

[42]  Linyan Zhu,et al.  Activation of ClC‐3 chloride channel by 17β‐estradiol relies on the estrogen receptor α expression in breast cancer , 2018, Journal of cellular physiology.

[43]  T. Luedde,et al.  IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies , 2018, International journal of molecular sciences.

[44]  Xiaoya Yang,et al.  Overexpression of CLC-3 is regulated by XRCC5 and is a poor prognostic biomarker for gastric cancer , 2018, Journal of Hematology & Oncology.

[45]  R. Medeiros,et al.  Pharmacogenomics in epithelial ovarian cancer first-line treatment outcome: validation of GWAS-associated NRG3 rs1649942 and BRE rs7572644 variants in an independent cohort , 2018, The Pharmacogenomics Journal.

[46]  R. Coletta,et al.  Clinicopathological significance of chemokine receptor (CCR1, CCR3, CCR4, CCR5, CCR7 and CXCR4) expression in head and neck squamous cell carcinomas , 2018, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[47]  C. Corrigan,et al.  Expression of IL-17A, E, and F and their receptors in non-small-cell lung cancer. , 2018, Journal of biological regulators and homeostatic agents.

[48]  I. Holen,et al.  Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment , 2019, Clinical Cancer Research.

[49]  H. Simon,et al.  IL-37: A new player in the chronic rhinosinusitis arena. , 2019, The Journal of allergy and clinical immunology.

[50]  T. de Baère,et al.  Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. , 2019, Cancer treatment reviews.

[51]  Mai Moaaz,et al.  Th17/Treg cells imbalance and their related cytokines (IL-17, IL-10 and TGF-β) in children with autism spectrum disorder , 2019, Journal of Neuroimmunology.

[52]  E. Tinazzi,et al.  In Systemic Sclerosis, a Unique Long Non Coding RNA Regulates Genes and Pathways Involved in the Three Main Features of the Disease (Vasculopathy, Fibrosis and Autoimmunity) and in Carcinogenesis , 2019, Journal of clinical medicine.

[53]  E. Suzuki,et al.  Paracoccidioides species present distinct fungal adherence to epithelial lung cells and promote different IL-8 secretion levels , 2019, Medical Microbiology and Immunology.

[54]  T. Chan,et al.  High TNFAIP6 level is associated with poor prognosis of urothelial carcinomas. , 2019, Urologic oncology.

[55]  She Chen,et al.  TREM2 acts as a tumor suppressor in hepatocellular carcinoma by targeting the PI3K/Akt/β-catenin pathway , 2019, Oncogenesis.

[56]  K. Goswami,et al.  TNF‐α mediated MEK–ERK signaling in invasion with putative network involving NF‐κB and STAT‐6: a new perspective in glioma , 2019, Cell biology international.